Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma

Michael P Randall, Huimin Geng, Lingjing Chen, Aishwarya Ballapuram, Chitoh Yung, Ming Lu, Gregory Chin, Michael Mish, Jamie Bates, James L. Rubenstein

Blood (2024) 144 (Supplement 1): 978.

https://doi.org/10.1182/blood-2024-212194

Published: 2024

Journal Articles

BTK Degradation As a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Patient-Derived, Rodent Models

Jun Ma, Michael P Randall, Ming Lu, Lingjing Chen, Huimin Geng, Aishwarya Kumar, Saloni Malla, Mark Noviski, Ryan Rountree, James L. Rubenstein

Blood (2024) 144 (Supplement 1): 2988.

https://doi.org/10.1182/blood-2024-211266

Published: 2024

Journal Articles

Engraftment Syndrome during Autologous Stem Cell Transplant in Hodgkin Lymphoma Patients Treated with Checkpoint Inhibitors: A Multi-Center Retrospective Analysis

Eleanor Taranto, Wei-Ting Hwang, Maria Alfaro, Annika S Surapaneni, Sarvarinder Kaur Gill, Tatyana Feldman, Michael P Randall, Michael A Spinner, Fateeha Furqan, Nirav N. Shah, Yazeed Samara, Matthew G. Mei, Alex F. Herrera, Alison Moskowitz, Gunjan L. Shah, Jakub Svoboda

Blood (2023) 142 (Supplement 1): 3603.

https://doi.org/10.1182/blood-2023-187199

Published: 2023

Journal Articles

Trial in Progress: A Phase I/II Study of Tafasitamab Plus Lenalidomide in Patients with Relapsed CNS Lymphoma

Michael P Randall, Andreas Rauschecker, Liam Gima-Lange, Jenai Wilmoth, Lingjing Chen, Ming Lu, Huimin Geng, Haifaa Abdulhaq, James L. Rubenstein

Blood (2023) 142 (Supplement 1): 3104.

https://doi.org/10.1182/blood-2023-190698

Published: 2023

Journal Articles

Favorable Outcomes for High-Risk MDS and Oligoblastic AML with MDS-Related Changes with Reduced Intensity Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide

Ilias Sinanidis, Michael Jamie Hochman, Hua-Ling Tsai, Michael P Randall, Brandon Bonilla, Ravi Varadhan, Alexander Joseph Ambinder, Amy E. DeZern, Theodoros Karantanos

Blood (2023) 142 (Supplement 1): 3229.

https://doi.org/10.1182/blood-2023-187247

Published: 2023

NARROW

Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma

BTK Degradation As a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Patient-Derived, Rodent Models

Engraftment Syndrome during Autologous Stem Cell Transplant in Hodgkin Lymphoma Patients Treated with Checkpoint Inhibitors: A Multi-Center Retrospective Analysis

Trial in Progress: A Phase I/II Study of Tafasitamab Plus Lenalidomide in Patients with Relapsed CNS Lymphoma

Favorable Outcomes for High-Risk MDS and Oligoblastic AML with MDS-Related Changes with Reduced Intensity Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide

Email alerts

ASH Publications

American Society of Hematology

Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma

BTK Degradation As a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Patient-Derived, Rodent Models

Engraftment Syndrome during Autologous Stem Cell Transplant in Hodgkin Lymphoma Patients Treated with Checkpoint Inhibitors: A Multi-Center Retrospective Analysis

Trial in Progress: A Phase I/II Study of Tafasitamab Plus Lenalidomide in Patients with Relapsed CNS Lymphoma

Favorable Outcomes for High-Risk MDS and Oligoblastic AML with MDS-Related Changes with Reduced Intensity Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only